Why Cancer Drugs Cross War Zones: The Fragile Geography of Medicine
Pharmaceutical supply chains don't follow logic—they follow legacy infrastructure. Right now, that means temperature-sensitive cancer medications bound for American hospitals are routing through Middle Eastern air hubs that are closing, rerouting, or operating under conflict conditions. It's not that drugs are made there. It's that the global cold-chain network—the refrigerated cargo system that keeps biologics stable—was built around a handful of transit chokepoints that happen to sit in a war zone.
Bottom Line
The Middle East conflict is stress-testing pharmaceutical supply chains in ways most people don't see until drugs aren't available. The core issue isn't manufacturing—it's the fragile, hub-dependent logistics network that moves temperature-sensitive medicines across continents. This is a preview of how modern supply chains, optimized for efficiency, fail when geopolitical stability breaks down in the wrong place. The impact will be felt in American pharmacies and hospitals as delayed shipments and sporadic shortages, particularly for cancer treatments and biologics that can't simply be rerouted without infrastructure.